Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

Someone asserted that dilutive financing was good. Well, that is never the case. Certainly, it is expected for a company at this stage, but well, the dilution in a couple of years went from 150 million shares to over a billion shares, and is now slated to quadruple from 8 million or so. ( The numbers may be off a little, the point is that the float has multiplied many times over. It seems like it is six, or seven, but it may be more than that. It is not less than that. I am sure.

Some companies continue to do that, and frankly, AMBS filed saying that they will have to quadruple the float from when they did the RS.

Again, the multiple may be three or actually, I think it is closer to five, but well, it is a lot.

That eplains the decrease in the share price. The prospect that more dilution is ahead, because the company said that it is ahead.

Now, ESS is a real product, however, the results will not be in for many years.

Estimated Enrollment: 10
Study Start Date: July 2015
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: July 2019 (Final data collection date for primary outcome measure)

https://clinicaltrials.gov/ct2/show/NCT01655407

So, you never know, until the trial is halted for obvious success, or completed, or the asset is sold, if ESS will bring in cash.

I tend to think the study will be positive, and at some point, because of that asset, and only that asset, AMBS will be a buy.

Why on earth they anounced a tripling of the A/S BEFORE uplisting is probably due to the rules, but it was not a good idea for the pps.

This may be the bottom, certainly, it is around here somewhere. But there are many years of trial before the end of this saga.

Now, you know what will boost the pps, but well, those things haven't happened, and if they could happen then they would because folks are looking forward to making money from the Naz.

The SOONEST someone will buy in ESS is when they see it work. Now, burns are not exactly something that you can double blind. It is out there for you to see. And so, if I were a pharma with money, I would keep track of the study.

It will not take that long for folks to get a clinical impression of its efficacy.

Bottom line, the competition should not be as good as ESS, because it is a full thickness graft for those who need full thickness grafts and do not have enough extra skin to move around, or stretch out, and then move around, because it is gone.

This was a good purchase, but the timing is bad, and the financing is massively dilutive.

GC bought WAY too many things at once. And over hyped them to the point of lying about everything but this product.

That said, it only takes one product.